Altimmune Announces Positive Results for ALT-702 in Preclinical Model of Colorectal Cancer
Preclinical study shows systemic activity of ALT-702 following local administration Altimmune granted U.S. patent providing broad coverage of platform technology GAITHERSBURG, Md., Jan. 23, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical …